• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Superficial radiation therapy may serve as promising cutaneous MCT treatment

May 17, 2023
dvm360 Staff

Results from a study display its possible effectiveness and safety

Sensus Healthcare Inc, a manufacturer of medical devices for non-surgical skin cancer and keloid scar treatment, announced that a study published in the Journal of the American Veterinary Medical Association1 has demonstrated that the company’s superficial radiation therapy SRT-100 system has potential effectiveness and safety for treating cutaneous mast Cell tumors (MCTs) in pets.

Traditionally, the treatment for cutaneous MCT treatment has involved surgery or chemotherapy. However, this limited retrospective case series analyzed the use of SRT as a non-invasive alternative for pets with MCT on the head. The results showed SRT treatment achieved a complete response in all cases that completed the intended protocol, with no significant adverse events reported.1

"The results of this limited retrospective case series are encouraging and demonstrate the potential of SRT-100 as a treatment option for MCTs,” stated Tiffany W. Martin, DVM, MS DACVR(RO), Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, in a company release.2

The study’s objective was to report preliminary findings of hypofractionated superficial radiotherapy for treatment of cutaneous mast cell tumors (MCTs) and report the acute and late toxicity connected with its use. Superficial radiation therapy was effective in the limited study population, and patients had minimal side effects for treatment of cutaneous MCTs.

Advertisement

Joe Sardano, chairman and CEO of Sensus Healthcare, added, in the release, “This study provides further evidence of the efficacy and safety of SRT. We're looking forward to bringing this non-invasive and cost-effective treatment option for the pet industry to market. Providing a less harmful radiation source with fabulous outcomes is of utmost concern to pet owners.

“SRT is mobile,” Sardano continued. “It can be placed in a mobile van to service several veterinary clinics in various sections of a community, region, or state. Treatments are fast and efficient for the vets to administer and extremely cost effective compared to higher energy and more costly devices.”1

References

  1. Martin TW, Prebble A, Leary D. Superficial kilovoltage x-ray radiotherapy for the treatment of cutaneous mast cell tumors on the head in three dogs and one cat: a limited retrospective case series. J Am Vet Med Assoc. 2023 Apr 28:1-6. doi: 10.2460/javma.23.02.0080.
  2. Sensus Healthcare's SRT treatment shows promise in treating cutaneous mast cell tumors among pet patients. News release. Sensus Healthcare Inc. May 17, 2023. Accessed May 17, 2023. https://www.globenewswire.com/news-release/2023/05/17/2670946/0/en/Sensus-Healthcare-s-SRT-Treatment-Shows-Promise-in-Treating-Cutaneous-Mast-Cell-Tumors-Among-Pet-Patients.html

Related Content:

OncologyProducts
Morris Animal Foundation funds study on environmental toxins and lymphoma
Morris Animal Foundation funds study on environmental toxins and lymphoma
Details of new pet performance supplement line revealed
Details of new pet performance supplement line revealed
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

Advertisement

Latest News

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

CityVet Celina opens in Prosper, Texas

View More Latest News
Advertisement